Collegium Pharmaceutical (COLL) Other Accumulated Expenses (2014 - 2025)

Collegium Pharmaceutical has reported Other Accumulated Expenses for 12 years, with the latest figure at $8.1 million in Q3 2025.

• On a quarterly basis, Other Accumulated Expenses rose 12.97% year-over-year to $8.1 million in Q3 2025; TTM through Sep 2025 was $8.1 million, a 12.97% increase from a year earlier, with the FY2024 full-year figure at $13.1 million, down 7.59% from the prior year.
• Other Accumulated Expenses was $8.1 million for Q3 2025 at Collegium Pharmaceutical, down from $14.0 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $14.3 million in Q2 2021, with the low at $6.8 million in Q3 2021.
• Average Other Accumulated Expenses over 5 years is $10.3 million, with a median of $8.1 million recorded in 2025.
• The sharpest annual moves came in 2021 and 2022: Other Accumulated Expenses dropped 23.34% in 2021, then soared 38.67% in 2022.
• Over 5 years, Other Accumulated Expenses stood at $9.9 million in 2021, then jumped by 38.67% to $13.8 million in 2022, then increased by 3.11% to $14.2 million in 2023, then declined by 7.59% to $13.1 million in 2024, then slumped by 38.13% to $8.1 million in 2025.
• The last three Other Accumulated Expenses figures came in at $8.1 million (Q3 2025), $14.0 million (Q2 2025), and $7.4 million (Q1 2025), per Business Quant data.